POPULATION OF CD3-NEGATIVE CELLS THAT EXPRESS CHEMOKINE RECEPTOR AND CELL ADHESION MOLECULE, USE OF THE SAME, AND METHOD FOR PRODUCING THE SAME

The present invention relates to an immunocyte having higher cytotoxic activity, and a pharmaceutical composition for NK cell therapies, for which high effect can be expected. The present invention provides a cell population including CCR5-positive, CCR6-positive, CXCR3-positive, and CD3-negative ce...

Full description

Saved in:
Bibliographic Details
Main Authors Harada, Yui, Yonemitsu, Yoshikazu
Format Patent
LanguageEnglish
Published 01.04.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to an immunocyte having higher cytotoxic activity, and a pharmaceutical composition for NK cell therapies, for which high effect can be expected. The present invention provides a cell population including CCR5-positive, CCR6-positive, CXCR3-positive, and CD3-negative cells. The present invention provides the cell population, wherein the CCR5-positive, CCR6-positive, CXCR3-positive, and CD3-negative cells further highly express CD11c. The present invention provides a CCR5-positive, CCR6-positive, CXCR3-positive, and CD3-negative cell, which infiltrates into a solid tumor. The present invention also provides a pharmaceutical composition containing such a cell population and a pharmaceutically acceptable additive. The present invention further provides a method for producing the aforementioned cell population.
Bibliography:Application Number: US201917041061